Illumina, Inc. vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Illumina, Inc. trades at $277.61 (market cap $39.95B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M). The key difference: Illumina, Inc. is far larger — about 422.9× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| ILMN | MSTZ | |
|---|---|---|
Market Cap | $39.95B | $94.46M |
Volume | 3,169,503 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $293.69 | $27.92 |
52-Week Low | $91.00 | $2.29 |
Typical Hold Time | 83 Days | 8 Days |
Enterprise Value | $41.31B | — |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
MSTZ trades at $2.58, down 3.01% with bearish technical signals from moving averages. The stock shows mixed momentum with neutral oscillators but negative moving average alignment. Key support sits at $2 with resistance at $3. Recent ETF coverage highlights the stock's inclusion in leveraged/inverse ETF discussions, though specific company fundamentals remain limited in available data.
Outlook remains cautious given technical weakness and limited fundamental visibility. The primary opportunity lies in potential technical rebounds from support levels, while risks include continued bearish momentum and lack of clear fundamental catalysts. Investors should await clearer financial metrics and earnings guidance for directional conviction.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →